CAR T-cells are gaining traction as a therapy for a variety of hematological malignancies. Here, Oliver Ottmann, MD, FRCPath, of Cardiff University, Cardiff, UK, discusses their role in acute lymphoblastic leukemia (ALL) at the 23rd Congress of the European Hematology Association (EHA) 2018, held in Stockholm, Sweden. He outlines the toxicities associated with CAR T-cells, including neurotoxicity and cytokine release syndrome, and also discusses the potential role for CAR T-cells in ALL treatment. Finally, he touches upon the possibility of combining CAR T-cell therapy with bispecific antibodies, and the impact this combination would have on toxicity and efficacy.
